3 Things You Need to Know if You Buy CRISPR Therapeutics Today

CRISPR Therapeutics (NASDAQ: CRSP) is recognized as a pioneer in the field of gene therapy. This biotechnology has the potential to revolutionize medicine through precise modifications of a person's DNA to treat and cure genetic diseases. In 2023, the company's Casgevy product for sickle cell disease became the first-ever CRISPR-based therapy approved by the Food and Drug Administration (FDA) as an important company milestone.Nevertheless, commercialization has been slow, with the market already waiting for the next possible blockbuster drug. At the time of writing, shares of CRISPR Therapeutics are down 46% from their 52-week high, leading investors to wonder what comes next. If you're considering buying stock in this gene therapy trailblazer, here are three things you should know.Part of the attraction of CRISPR Therapeutics as an investment is its first-mover advantage, which counts on several patented processes for CRISPR diagnostic and therapeutic applications. The approval of Casgevy, co-developed with Vertex Pharmaceuticals, validated its technology to move forward with a broader pipeline of drug candidates.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool